Nano Dimension to merge with Infinite Epigenetics for $890M
Nano Dimension Ltd. announced a non-binding term sheet for a proposed business combination with Infinite Epigenetics, an AI-powered preventive health and diagnostics company. The transaction values Infinite Epigenetics at $890 million and aims to deploy Nano Dimension's capital base and Nasdaq listing into a high-growth healthcare AI opportunity. Existing Nano shareholders are expected to retain a meaningful minority ownership, with their shares valued at a 20% premium to Nano's estimated net cash at closing, and the combined company is projected to have over $400 million in cash. Infinite Epigenetics focuses on a $90B+ U.S. clinical diagnostics market, leveraging a proprietary biological AI platform and over 120,000 epigenetic samples collected since 2020.
Key Highlights
- Nano Dimension to combine with Infinite Epigenetics, an AI-powered preventive health and diagnostics company.
- Infinite Epigenetics transaction valued at $890 million.
- Nano Dimension shareholders to retain meaningful minority ownership, reflecting a 20% premium to Nano's estimated net cash.
- Combined company expected to have over $400 million in cash at closing.
- Infinite Epigenetics targets a $90B+ U.S. clinical diagnostics market opportunity.
- Infinite Epigenetics has collected over 120,000 epigenetic samples since 2020.
- The parties have entered a 30-day period of mutual exclusivity for due diligence and definitive agreement negotiation.
- Dr. Matthew Dawson is expected to serve as CEO of the combined company.
Price Impact
More from NNDM